New cell therapy targets tough cancers in early trial
Disease control
Not yet recruiting
This early-phase study tests DCTY1102, a personalized cell therapy, in 18 adults with advanced colorectal, lung, or pancreatic cancers that have a specific KRAS/NRAS G12D mutation and HLA type. Participants receive a single infusion of their own genetically modified immune cells …
Phase: PHASE1 • Sponsor: Beijing DCTY Biotech Co.,Ltd. • Aim: Disease control
Last updated May 26, 2026 10:30 UTC